PubRank

Mitch A Phelps

Author PubWeight™ 45.64‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2006 3.16
2 Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 2011 2.59
3 Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others. Cleve Clin J Med 2011 2.43
4 Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009 2.34
5 Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol 2011 1.65
6 A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma 2009 1.58
7 miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res 2011 1.51
8 Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res 2013 1.51
9 Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2). Biochemistry 2004 1.33
10 Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 2005 1.27
11 Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010 1.20
12 Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 2010 1.17
13 Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells. AAPS J 2011 1.11
14 Program in pharmacogenomics at the Ohio State University Medical Center. Pharmacogenomics 2012 1.07
15 Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One 2010 0.99
16 Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach. Haematologica 2012 0.99
17 Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Ther Drug Monit 2008 0.98
18 A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Invest New Drugs 2010 0.96
19 Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry. AAPS J 2011 0.95
20 A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clin Cancer Res 2013 0.94
21 Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides. Bioorg Med Chem 2006 0.91
22 Favorable effects of weak acids on negative-ion electrospray ionization mass spectrometry. Anal Chem 2004 0.90
23 Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. Am J Hematol 2013 0.87
24 Involvement of endocytic organelles in the subcellular trafficking and localization of riboflavin. J Pharmacol Exp Ther 2003 0.86
25 Modeling of active transport systems. Adv Drug Deliv Rev 2002 0.86
26 A phase I trial of flavopiridol in relapsed multiple myeloma. Cancer Chemother Pharmacol 2013 0.84
27 A novel liposomal formulation of flavopiridol. Int J Pharm 2008 0.84
28 A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors. Invest New Drugs 2012 0.84
29 Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. J Pharm Biomed Anal 2013 0.81
30 Intracellular processing of riboflavin in human breast cancer cells. Mol Pharm 2008 0.80
31 Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J 2012 0.80
32 Influence of exercise on the distribution of technetium Tc 99m medronate following intra-articular injection in horses. Am J Vet Res 2012 0.80
33 Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 2013 0.80
34 Recognition, co-internalization, and recycling of an avian riboflavin carrier protein in human placental trophoblasts. J Pharmacol Exp Ther 2006 0.79
35 Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes. Nanomedicine 2012 0.79
36 Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. Clin Pharmacokinet 2013 0.77
37 Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue. J Chromatogr B Analyt Technol Biomed Life Sci 2012 0.76
38 Inhibitors of tubulin assembly identified through screening a compound library. Chem Biol Drug Des 2008 0.76
39 Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008 0.76
40 Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). Am J Hematol 2015 0.75
41 Acetaminophen pediatric dose selection: caregiver satisfaction regarding the antipyretic efficacy of acetaminophen in children. Clin Pediatr (Phila) 2012 0.75
42 Pharmacokinetics of methylprednisolone acetate after intra-articular administration and subsequent suppression of endogenous hydrocortisone secretion in exercising horses. Am J Vet Res 2012 0.75
43 Analysis of the transport of and cytotoxic effects for nalbuphine solution in corneal cells. Am J Vet Res 2012 0.75